{
    "organizations": [],
    "uuid": "37ad4d6431dcaa98adb1012cca0d2d014a55c877",
    "author": "",
    "url": "https://www.reuters.com/article/brief-prometic-reports-positive-clinical/brief-prometic-reports-positive-clinical-data-from-its-intravenous-immunoglobulin-pivotal-phase-3-trial-idUSASC09Y5K",
    "ord_in_thread": 0,
    "title": "BRIEF-Prometic Reports Positive Clinical Data From Its Intravenous Immunoglobulin Pivotal Phase 3 Trial",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 30, 2018 / 10:50 AM / Updated 9 minutes ago BRIEF-Prometic Reports Positive Clinical Data From Its Intravenous Immunoglobulin Pivotal Phase 3 Trial Reuters Staff\nApril 30 (Reuters) - Prometic Life Sciences Inc:\n* PROMETIC REPORTS POSITIVE CLINICAL DATA FROM ITS INTRAVENOUS IMMUNOGLOBULIN (IVIG) PIVOTAL PHASE 3 TRIAL\n* PROMETIC LIFE SCIENCES INC - PIVOTAL CLINICAL TRIAL MEETS PRIMARY AND SECONDARY ENDPOINTS\n* PROMETIC LIFE SCIENCES INC - CLINICAL DATA DEMONSTRATES COMPARABLE EFFICACY TO COMMERCIALLY-APPROVED DRUG\n* PROMETIC LIFE SCIENCES INC - PROMETIC IVIG’S SAFETY AND TOLERABILITY PROFILES MAINTAINED WITHOUT ANY SIGNIFICANT DRUG RELATED ISSUES\n* PROMETIC LIFE SCIENCES INC - PROMETIC IVIG’S SAFETY AND TOLERABILITY PROFILES MAINTAINED WITHOUT ANY SIGNIFICANT DRUG RELATED ISSUES\n* PROMETIC LIFE SCIENCES INC - OVERALL PROMETIC IGIV 10% APPEARED TO BE WELL TOLERATED AND WAS NOT ASSOCIATED WITH ANY SBIS Source text for Eikon: Further company coverage:",
    "published": "2018-04-30T13:46:00.000+03:00",
    "crawled": "2018-04-30T14:07:13.006+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "updated",
        "minute",
        "ago",
        "report",
        "positive",
        "clinical",
        "data",
        "intravenous",
        "immunoglobulin",
        "pivotal",
        "phase",
        "trial",
        "reuters",
        "staff",
        "april",
        "reuters",
        "prometic",
        "life",
        "science",
        "inc",
        "prometic",
        "report",
        "positive",
        "clinical",
        "data",
        "intravenous",
        "immunoglobulin",
        "ivig",
        "pivotal",
        "phase",
        "trial",
        "prometic",
        "life",
        "science",
        "inc",
        "pivotal",
        "clinical",
        "trial",
        "meet",
        "primary",
        "secondary",
        "endpoint",
        "prometic",
        "life",
        "science",
        "inc",
        "clinical",
        "data",
        "demonstrates",
        "comparable",
        "efficacy",
        "drug",
        "prometic",
        "life",
        "science",
        "inc",
        "prometic",
        "ivig",
        "safety",
        "tolerability",
        "profile",
        "maintained",
        "without",
        "significant",
        "drug",
        "related",
        "issue",
        "prometic",
        "life",
        "science",
        "inc",
        "prometic",
        "ivig",
        "safety",
        "tolerability",
        "profile",
        "maintained",
        "without",
        "significant",
        "drug",
        "related",
        "issue",
        "prometic",
        "life",
        "science",
        "inc",
        "overall",
        "prometic",
        "igiv",
        "appeared",
        "well",
        "tolerated",
        "associated",
        "sbis",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}